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Abstract
Background: Gastrointestinal (GI) lymphomas are very common types of extranodal lymphomas, and we
hypothesize there are regional differences in subtype, distribution in the GI tract, and epidemiological features
among the different populations.
Methods: We retrospectively evaluated the clinical, molecular and histologic features of North American primary and
secondary GI lymphomas diagnosed from 2000–2009 seen at our institution. We utilized immunohistochemistry and
fluorescence in situ hybridization to further evaluate a subset of the gastric lymphomas.
Results: Extranodal marginal zone lymphomas of mucosal associated lymphoid tissue (MALTs) and diffuse large B cell
lymphomas (DLBCLs) were the most common subtypes of GI lymphomas. Select gastric DLBCLs (N= 6) and MALTs
(N= 13) were further examined for API2-MALT1 and IGH translocations, and P16 and P53 protein expression. Gastric
MALTs showed frequent API2-MALT1 (38%) but not IGH translocations (0%), and the DLBCLs showed neither
translocation. Expression of P16 and P53 proteins and the proliferative index were compared between high grade
gastric lymphomas (gastric DLBCLs) and low grade gastric lymphomas (gastric MALTs). P53 overexpression (P= 0.008)
and a high proliferation index [Ki-67] (P= 0.00042) were significantly associated with gastric DLBCL, but no statistically
significant difference was observed in P16 expression (p= 0.108) between gastric DLBCL and gastric MALT.
Conclusion: Our study revealed that GI lymphomas from a Central-Midwestern North American population showed
differences and similarities to non-North American cohorts. In addition, API2-MALT1, P16 and P53 abnormalities
occurred frequently in gastric lymphomas from this North American population.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1415505838687793
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Introduction
Gastrointestinal (GI) lymphomas are a relatively com-
mon type of extranodal lymphoma, accounting for up to
30-50% of extranodal lymphomas in some series [1,2].
However, the majority of population based studies have
been performed on Asian or European cohorts [2-9]
with only one recent study from a Canadian-North
American cohort [10]. Though studies from the United
States (US) have been performed, most are several dec-
ades old, and use nomenclature that predates the
current World Health Organization (WHO) classifica-
tion for lymphomas [11,12]. It is established that the
prevalence of many gastrointestinal malignancies differs
between continents. For example, the incidence of gas-
tric adenocarcinoma is known to be substantially higher
in Japan than in the US [13]. Therefore, it stands to rea-
son that the distribution of different lymphoma subtypes
in the GI tract may differ between North America and
other continents.
Specific genetic and epigenetic factors play a role in
the pathogenesis of many lymphomas, including translo-
cations (i.e. API2-MALT1, CCND1-IGH) [14], defects in
tumor suppressor genes (i.e. RB1, TP53, p15/CDKN2B)
[15-19], and promoter hypermethylation of tumor sup-
pressor genes (i.e. p16/CDKN2A) [20-22]. Promoter
hypermethylation of p16/CDKN2A occurs quite fre-
quently in gastric lymphoid follicles with Helicobacter
pylori infection, gastric marginal zone lymphomas of
mucosal associated lymphoid tissues (MALTs), and gas-
tric diffuse large B cell lymphomas (DLBCLs), account-
ing for 10%, 41.7% and 72.7% of these cases, respectively
in a Korean study [22]. Some genetic perturbations have
been shown to be characteristic of specific lymphomas
of the GI tract. For example, the t(11;18)(q12;q21);
API2-MALT1 is relatively common in gastric MALTs,
while it is less common in pulmonary MALTs, and is vir-
tually never found in MALTs from other locations [14].
Epidemiologic factors, such as Helicobacter pylori infec-
tion in gastric MALTs [14], are also known to be asso-
ciated with some lymphoma subtypes.
Systemic lymphomas may secondarily involve the GI
tract. However, the subtypes of lymphomas that affect
the GI tract primarily versus secondarily have not been
comprehensively detailed.
In the current study, we evaluated primary and sec-
ondary GI lymphomas diagnosed at Washington Univer-
sity Medical Center over the 10 year period from 2000–
2009. We determined the frequency of involvement of
different anatomic locations in the GI tract by different
lymphoma subtypes. Gastric DLBCLs and MALTs were
further studied to determine P16 and P53 expression,
and the presence of IGH and API2-MALT1 rearrange-
ments, to establish frequencies of these alterations in
cases from a Central North American population. Our
studies highlight there are distinct clinicopathologic fea-
tures of primary and secondary GI lymphomas from a
Central-Midwestern North American cohort.
Material and methods
Patient selection
All aspects of this study were approved by an internal
ethics committee at Washington University.
We retrospectively examined cases of GI lymphomas
diagnosed at Washington University from January 2000
to December 2009. A total of 242 cases were included in
this study, including 216 primary and 26 secondary GI
lymphomas, among which 64 were initially diagnosed in
our institution and 178 were referred from outside insti-
tutions. Primary GI lymphoma was defined as cases pre-
senting with GI symptoms or predominant tumor(s)
location in the GI tract [23]. Secondary GI lymphomas
were diagnosed when patients had a prior diagnosis of
lymphoma that later recurred in the GI tract (esophagus,
stomach, small intestine, large intestine). Lymphoma
cases from patients in the post-transplant setting were
excluded. All patients were classified according to the
World Health Organization (WHO) 2008 criteria [24].
Staging was performed according to the Ann Arbor clas-
sification modified by Musshoff for the digestive tract
[25,26]. Clinical history, including Helicobacter pylori
(HP) infection (by positive histology or serologic testing),
imaging studies, and patients’ chart review were per-
formed to categorize these cases as primary or secondary
GI lymphomas. Sites of involvement were recorded.
Among the 64 primary GI lymphomas initially diagnosed
at our institution, there were 30 DLBCLs, 19 MALTs, 4
follicular lymphomas (FLs), 3 anaplastic large cell
lymphomas (ALCLs), 2 mantle cell lymphomas (MCLs),
4 Burkitt lymphomas (BLs), and 2 other non-ALCL T
cell lymphomas. 12 gastric DLBCLs and 16 gastric
MALTs were initially diagnosed at our institution, and
sufficient tissue was available on 6 gastric DLBCLs and
13 gastric MALTs to perform additional tests (immuno-
histochemistry for P16, P53, and Ki-67 and fluorescence
in sit hybridization studies [FISH]). 1 duodenal MALT
was also evaluated by immunohistochemistry for P16,
P53, and Ki-67 and FISH. 3 benign chronic gastritis bi-
opsies with lymphoid hyperplasia were also evaluated by
immunohistochemistry for P16 and P53.
Immunohistochemistry
All tissues were obtained by endoscopic biopsy or sur-
gery, fixed in 10% neutral buffered formalin, and then
sectioned at 4 μm to evaluate by immunohistochemistry.
The following antibodies were analyzed: P16 (Clone
INK4a, MTM laboratories, prediluted), P53 (Bp-53-11,
Ventana, Prediluted), and Ki-67 (Clone 30–9, Ventana,
prediluted). All immunohistochemical stains were
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blinded and independently reviewed by two pathologists
(J.W. and T.N.) and discrepancies were settled over a
multiheaded scope.
P16 and P53 immunostaining was scored as follows: 0,
no to≤ 5% of lesional cells positive; 1, >5% to< 20% of
lesional cells positive; 2, ≥ 20% of lesional cells positive,
regardless of staining intensity. Staining was performed
using the BenchMark XT (Ventana, Tusco, AZ), and
antibody detection with UltraView Universal 3,3’-diami-
nobenzidene detection system (Ventana). Ki-67 was
scored by the presence of positive nuclear staining in the
lesional cells.
Interphase fluorescence in situ hybridization analysis
The presence of immunoglobulin heavy chain (IGH) and
API2-MALT1(Vysis LSI BIRC3/MALT1 dual color dual
fusion) translocations were examined by a bicolor FISH
detection system, using a dual color break apart probe
and dual color fusion probe respectively (Abbott Mo-
lecular, Downer’s Grove, IL, USA), according to manu-
facturer’s recommendations and laboratory protocol
previously described [27]. Nuclei were then counter-
stained with DAPI (0.5 l/ml) and the sections were
examined using an Olympus BX51 or BX61 fluorescent
microscope with appropriate filters (Olympus, Melville,
NY, USA). At least one hundred non-overlapping nuclei
were examined for each probe. The IGH break apart re-
arrangement probe was scored positive if a split signal
pattern with a split of red and green signals were seen in
at least 10% of the cells analyzed. The API2-MALT1
probe was read as positive if at least 5% cells with 2 fu-
sion signals (yellow), 1 red signal and 1 green signal were
seen.
Statistical analysis
Fisher’s exact test was conducted to test association be-
tween P16 and P53 expression with lymphoma grade,
while Ki-67 proliferation index between patients of low
and high grade lymphoma was compared using Wil-
coxon rank sum test. Low grade lymphomas were
defined as gastric MALTs for our statistical analysis.
High grade lymphomas were cases that met criteria for
gastric DLBCL. Gastric MALTs with admixed large B
cells were classified as low grade lymphomas in our stat-
istical analysis. Statistical significance was deemed at the
5% level. All analyses were conducted in R2.13.1.
Results
Subtype and site of involvement for the primary GI
lymphomas
The primary GI lymphomas in our series are depicted by
anatomic site and lymphoma subtype in Additional file 1
Table S1. Intestinal lymphomas (n = 116) were more
common than gastric lymphomas (n = 97), with the large
intestine (excluding the rectum) being the most com-
mon site of involvement in the intestine. In analyzing
both the in house primary GI lymphomas and primary
GI lymphomas diagnosed initially at an outside institu-
tion which were referred to our medical center for treat-
ment, gastric DLBCLs and gastric MALTs accounted for
the greatest numbers of lymphomas. Although DLBCL
was the most common lymphoma type in the intestine,
accounting for 33% of cases, follicular lymphoma [FL]
(21%) and mantle cell lymphoma [MCL] (22%) also
comprised a considerable fraction of cases in this site.
Burkitt lymphoma (9%) appeared to be primarily an in-
testinal lymphoma among our cases. MALTs were less
common (10% of intestinal cases), and the majority of
cases occurred in the duodenum. Similar to the intes-
tinal cases, DLBCL was the most common lymphoma
type in the stomach, accounting for 48% of cases. In
contrast to the intestine, MALT was the second most
common type (44%) in the stomach. Gastric FL (1%), T-
cell non-Hodgkin lymphoma (2%), and MCL (2%) were
distinctly uncommon. Excluding MCL, which tends to
involve many sites of the intestinal tract, we identified
three cases of primary GI lymphomas involving multiple,
non-contiguous sites. Two were DLBCLs involving the
stomach and cecum, and the other was an anaplastic
large cell lymphoma (ALCL) involving the duodenum
and large intestine.
Patient demographics
The median age and sex distribution of the primary GI
lymphoma cases are listed in Additional file 2 Table S2.
A male predominance was seen in intestinal MALT (5:1
male:female), intestinal DLBCL (1.7:1 male:female), and
intestinal Burkitt lymphoma (1:0 male:female). The
remaining lymphoma subtypes showed either no consid-
erable sex predominance or were present in insufficient
numbers to make a determination. Gastric and intestinal
DLBCLs, MALTs, and FLs tended to affect patients in
the sixth and seventh decade, while intestinal Burkitt
lymphomas tended to affect a younger cohort, with a me-
dian age of 41 years. Review of the clinical charts revealed
Helicobacter pylori infection occurred in approximately
24% of gastric MALTs and 9% of gastric DLBCLs by posi-
tive serology or histology. Stage of diagnosis was examined
in all gastric MALTs and DLBCLs that had adequate
radiographic data available. Gastric DLBCLs presented
more frequently at a higher stage (i.e. stage III or IV) com-
pared to the gastric MALTs (72% vs. 3%). The majority of
gastric MALTs were stage IE or IIE.
Immunophenotype, expression of P16 and P53, and
proliferation index in gastric lymphomas
Six gastric DLBCLs had sufficient tissue for evaluation
with immunohistochemistry, and the results are
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summarized in Additional file 3 Table S3. All 6 cases
were negative for CD10 and CD5. All gastric DLBCLs
showed a high proliferative index, with a Ki-67 index
≥80%. In contrast, the gastric MALTs had lower Ki-67
rates (≤20%) in the majority of cases. Rare (2/13) cases
of gastric MALT showed a higher proliferative index of
~50%, which were those with increased admixed larger
cells (see Additional file 3 Table S3, MALT cases noted
by **).
Expression of P16 and P53 in 3 benign chronic gastri-
tis biopsies was evaluated to establish a baseline. P16 ex-
pression was low or absent in the chronic gastritis cases,
while P53 was not overexpressed in any of these benign
cases. All gastric DLBCLs showed P53 expression, and
frequent overexpression (score 2 in 83%) was observed
in the gastric DLBCLs. 3 gastric DLBCLs (50%) also
showed P16 expression. Among the 13 gastric MALTs
evaluated, only two (15%), which also had increased
large cells and a higher Ki-67 index, showed overexpres-
sion of P53 (defined as score 2 or ≥ 20% tumor cells
positive), while the majority (85%) lacked P53 over-
expression. P16 expression was seen in only 2 (15%) of
gastric MALTs. We compared the P16 and P53 expres-
sion and proliferative index between high grade gastric
lymphomas (gastric DLBCLs) and low grade gastric
lymphoma (gastric MALTs). A statistically significant as-
sociation between P53 overexpression and gastric
DLBCL was noted (p = 0.008). Ki-67 level was also asso-
ciated with gastric DLBCL using a Wilcoxon rank sum
test (p = 0.00042). However, no statistically significant
difference was observed in P16 expression between gas-
tric DLBCL and gastric MALT (p = 0.108). Figure 1
demonstrates the histology, Ki-67 expression, and P53
expression in a gastric MALT and a gastric DLBCL
showing the most common expression profile for each
type.
FISH evaluation for API2-MALT1 and IGH translocations in
gastric lymphomas
5 of 13 (38%) cases of gastric MALTs were positive for
the API2-MALT1 translocation, while all 13 cases were
negative for the IGH translocation. A single duodenal
MALT was positive for the IGH translocation, but nega-
tive for the API2-MALT1. All 6 gastric DLBCLs were
negative for IGH and API2-MALT1 translocations.
Subtype and site of involvement of secondary GI
lymphomas
Secondary involvement of the GI tract by lymphoma
was considerably less common than primary GI lymph-
oma (26 secondary vs. 216 primary cases). DLBCL was
the most common lymphoma type to secondarily involve
the GI tract, accounting for the majority of intestinal
(57%), gastric (80%), and esophageal (100%) cases.
Gastric involvement was more common than intestinal
or esophageal involvement. A handful of cases of FL,
ALCL, Burkitt lymphoma, small lymphocytic lymphoma,
and T-cell non-Hodgkin lymphoma also showed second-
ary involvement of the GI tract, while no secondary
cases of MALT or B or T lymphoblastic lymphoma were
identified in our series. The results are summarized in
Additional file 1 Table S1.
Discussion
We undertook this 10 year retrospective study to evalu-
ate the clinicopathologic and molecular features of GI
lymphomas at a major US tertiary care medical center to
determine the features of GI lymphomas in North
America in comparison to other non-North American
lymphoma cohorts. No previous extensive US study de-
scribing the primary and secondary GI lymphomas pre-
senting in a Northern American population has been
published that utilizes the current World Health
Organization lymphoma classification. We show that
there are distinct differences and similarities in our cases
compared to other population based studies. Although
many types of GI lymphomas were diagnosed, most of
the cases presenting to our facility were referral cases
initially diagnosed as lymphoma at an outside facility
which were later referred to our facility for additional
treatment. Thus, many of these patients had been trea-
ted with many different therapeutic regimens, so treat-
ment regimens varied greatly among our cases and were
too heterogenous to correlate treatments with clinical
outcome in our analysis.
Several series from Europe, Canada-North America,
and Asia have reported on primary GI lymphomas by
lymphoma type and anatomic site [2-5,7,9,28-30]. Sev-
eral trends emerge when reviewing the data collectively.
First, primary gastric lymphomas tended to be more
common than primary intestinal lymphomas in the
European and Asian studies. Intestinal cases accounted
for only 14%, 19%, 21%, 10%, 30%, 34%, 50% and 43% of
cases in the Greek, Japanese, German, Austrian, Serbian,
Turkish, Canadian-North American and Danish studies,
respectively [2-5,7,9,28-30]. Gastric lymphomas accounted
for >50% of total cases in most of these series. Our study
stands in contrast to these, in that intestinal cases out-
number gastric cases, accounting for 54% of total primary
GI lymphomas. This difference noted in our study could
be due to lower prevalence rates of HP infection in the US
resulting in fewer gastric MALTs diagnoses, earlier treat-
ment for HP infection resulting in fewer cases progressing
to gastric MALTs, or that US patients with intestinal in-
volvement have more severe symptoms such as intestinal
obstruction and/or easier health care access resulting in
more frequent visits to our tertiary care surgery facilities
than patients with only solitary gastric involvement. The
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second trend to emerge is that high grade gastric lymph-
omas (i.e. gastric DLBCLs) tend to occur in approximately
equal proportion to low grade gastric lymphomas (i.e. gas-
tric MALTs). In this regard, our data are consistent with
the European and Asian studies. Third, MALTs are much
more common in the stomach than other sites, while
DLBCLs tend to affect all segments of the GI tract. Our
series also shows this trend to hold true.
Our study is also consistent with a recent study of pri-
mary GI FL from France by Damaj et al., which showed
that primary FL of the GI tract tends to be a disease of
the small intestine [31]. Similar findings were reported
in a recent large US study which revealed small intes-
tinal FLs made up 63% of cases while gastric FLs
accounted for only 3% of primary gastrointestinal FLs
[32]. Similarly, 14 of the 25 (56%) of primary FLs in our
series were found in the small intestine. No other low
grade B lymphoma type in our series showed such a
strong propensity for small intestinal involvement. In
contrast to the study by Damaj et al., which showed a fe-
male predominance, the small intestinal FLs in our series
were equally distributed among men and women.
In examining the stage of presentation in our gastric
MALTs and gastric DBLCLs, we also noted that gastric
DLBCLs tended to have higher stage disease at presenta-
tion, while gastric MALTs often showed lower stage dis-
ease at presentation. Previous studies have shown that
stage of lymphoma is an important prognostic predictor
of clinical outcome, and that the lower grade gastric
MALTs tend to have low stage while higher grade
Figure 1 A,C, and E depict a low grade gastric marginal zone lymphoma of mucosal associated lymphoid tissue (MALT). B, D, and F
depict a gastric diffuse large B cell lymphoma (DLBCL). (A) MALT in a gastric biopsy (H&E, 400X). (B) DLBCL in a gastric biopsy (H&E, 600X). (C) Ki-
67 shows a low proliferative index in a low grade MALT (Ki-67 immunohistochemistry, 200X). (D) Ki-67 shows a high proliferative index, 100%, in
this DLBCL. The negatively stained cells are the glandular epithelial cells. (Ki-67 immunohistochemistry, 400X). (E) P53 protein is absent in the
tumor cells of a MALT, while weak nuclear P53 staining is seen in the adjacent benign glandular epithelium (P53 immunohistochemistry, 1000X).
(F) P53 protein overexpression is noted in the tumor cells of this DBLCL, while the cells negative for nuclear P53 immunostaining are benign
glandular epithelial cells. (P53 immunohistochemistry, 1000X).
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DLBCLs tend to have higher stage at presentation
[3,4,28,33]. Thus, our study reveals that this association
also occurs in the lymphomas from a Central North
American population.
Environmental factors, especially Helicobacter pylori
(HP) infection, have been noted to play a prominent role
in the development of gastric lymphomas [34]. In 2 Ital-
ian studies, HP has been reported to occur in 88% of
low grade gastric MALTs identified by histologic exam-
ination, while it occurred at lower frequency (52-63%) in
high grade gastric lymphomas [28,35]. Interestingly, both
Italian studies revealed a statistically significant associ-
ation between HP infection and low grade gastric
lymphoma (p< 0.0001) [28,35]. Similarly, a serologic
study performed at a New York center showed HP sero-
prevalence up to 67% in gastric MALTs, and increased
seropositive rates were associated with increased age and
country of birth outside the US or Canada (p = 0.0001)
[34]. Interestingly, HP infection in our study was seen in
only 24% of the gastric MALTs and 9% of the gastric
DLBCLs by positive serology or histology, and we also
noted higher frequency of HP infection in the low grade
gastric MALTs compared to high grade gastric DLBCLs.
A 2008 Canadian-North American study also showed
HP infection in 20% of gastrointestinal non-Hodgkin
lymphomas, of which 44% were in MALTs and 13% were
in DLBCLs [10]. The less frequent HP infection rates in
our cases could relate to our patient population having a
higher percentage of patients born in the US or Canada,
differences in the ethnicities of the Central-Midwestern
compared to the New York population, or lower preva-
lence of HP infection in the Midwest. Alternatively, the
absence of serologic testing in all our cases, which may
be more sensitive than histology in detecting HP infec-
tions, could also contribute to a lower HP prevalence
rate in our gastric MALT patients.
Because of the high prevalence of genetic defects in
p16/CDNK2A in non-Hodgkin B cell lymphomas, we
also evaluated P16 expression in our gastric MALTs and
DLBCLs. Previous studies have shown that P16 is under-
expressed more frequently in gastric MALT than in
other lymphoma types [20,21]. This has been shown to
primarily relate to p16 promoter hypermethylation in
non-transformed MALTs [20,36,37]. As such, p16 hyper-
methylation, and the resulting loss of P16 protein, is a
high-frequency event in gastric MALTs occurring in up
to 75% to 79% of cases in some studies [20-22,38,39].
One Korean study by Min et al. also showed increased
frequency of p16 hypermethylation in gastric DLBCLs
(N= 11, 72.7%) compared to gastric MALTs (N= 24,
41.7%) and proposed that malignant transformation of
gastric MALTs was attributed in part to p16 hyper-
methylation [22]. Our results confirm the prior findings
that p16 is frequently inactivated in gastric MALTs, since
P16 expression was absent in 11 of 13 (85%) gastric
MALTs, and expression was scored as 0 (i.e. less 5% of
tumor cells positive) in these cases. In addition, P16 was
expressed in only 3 of the 6 (50%) gastric DLBCLs. Most
p16 hypermethylation has been previously seen in HP
dependent cases. This fact may explain the weak P16 ex-
pression seen in one HP+ gastritis case we tested, but
does not provide a mechanism for P16 loss in the our
HP- gastritis cases and HP- gastric MALTs. Although
the overall numbers of cases analyzed for P16 expression
is low, our study showed no statistically significant dif-
ference was observed in P16 expression between gastric
DLBCL and gastric MALT (p = 0.1078). Our result dif-
fers from the Korean study by Min et al. that showed
hypermethylation of p16 (which can consequently down-
regulate P16 expression) to be more frequently asso-
ciated with gastric DLBCLs compared to low grade
gastric MALTs [22]. Since the number cases in our study
is only half as many as studied by Min et al., other stud-
ies would be needed to determine if this association be-
tween p16 hypermethylation (P16 expression loss) in
high grade gastric DLBCLs holds true in other
populations.
P53 over-expression has been shown to correlate with
mutations in TP53 [40]. This may relate to decreased
rate of degradation of the mutant protein, leading to ele-
vated cytoplasmic accumulation. P53 immunohisto-
chemistry may be useful in evaluating primary GI
lymphomas, because P53 accumulation has been shown
to be more common in high grade lymphomas than low
grade lymphomas [41]. Moller et al. showed that P53
protein overexpression, defined as ≥ 20% of tumor cells
positive for P53, was 80-90% sensitive and 100% specific
in predicting TP53 mutations in DLBCLs [42]. Moller
et al. also reported that p53 overexpression was an inde-
pendent predictor of poor outcome in both T and B
non-Hodgkin lymphomas (n = 199), and that P53 pre-
dicted poorer overall survival in indolent and aggressive
non-Hodgkin lymphomas in addition to being associated
with treatment failure and relapse-free survival. Using
the same scoring criteria, high grade gastric DLBCLs
were more significantly associated with P53 overexpres-
sion than low grade gastric MALTs in our series
(p = 0.008). Thus our data corroborates the prior studies
which have suggested mutations in TP53 may relate to
progression from low grade to high grade lymphoma, as
well as increased risk of relapse [19,42].
Increased Ki-67 index has also been shown to correlate
with increased grade of lymphoma [41]. Our results were
consistent with these previous observations, since all of
our tested gastric DLBCLs had high Ki-67 index ≥80%,
while the majority (85%) of the gastric MALTs had Ki-67
≤20%. Statistical analysis on our lymphomas also showed
higher Ki-67 levels were significantly associated with high
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grade lymphoma, specifically gastric DLBCL (p= 0.00042).
Of note, the two MALTs with the highest Ki-67 index
(50%) both showed strong P53 expression and an
increased admixture of large B cells. This suggests they
are not typical low grade MALTs, and likely are intermedi-
ate or transitional cases between a low grade and a high
grade gastric B cell lymphoma. Alternatively, since these
two gastric MALTs were diagnosed from small endoscopic
biopsies, undersampling of a DLBCL on a small biopsy
could also explain the P53 overexpression in these two
outlier cases. Identification of a high proliferative index
(Ki-67 >80%) on small gastric biopsies is also a helpful
feature in diagnosing DLBCL, since all low grade gastric
MALTs lacking evidence of large cell transformation (or
admixed large cells) tend to show lower Ki-67 levels
(≤20%). Assessment of the proliferative index may be a
useful feature to study in small gastric biopsies with sig-
nificant crushed features where morphologic evaluation is
limited, and optimal grading and subtyping of the B cell
lymphomas can be challenging due to the suboptimal
quality of the biopsy.
The API2-MALT1 translocation has been shown to be
relatively frequent in gastric MALTs, and has been
shown to predict both lack of resolution with H. pylori
eradication [43] and resistance to further genetic damage
[44,45]. Perhaps unsurprisingly, this translocation has
been reported to be a rare event in gastric DLBCLs
[20,45-47], indicating a gastric MALT with this trans-
location rarely progress to gastric DLBCL. Our series
confirm these previous findings, as none of our gastric
DLBCLs showed the API2-MALT1 translocation, and
none of the gastric MALTs with this translocation had
concomitant HP infection. In addition, this translocation
was quite frequent (38%) in the gastric MALTs in our
series, similar to the 17%-40% reported in other studies
[17,18,30,48,49].
Although IGH translocations such as t(1;14)(p22;q32);
BCL10-IGH are reported in 3% of gastric MALTs and 5-
10% of intestinal MALTs [17,18], we did not detect fre-
quent IGH translocations in this series, as our tested
gastric MALTs were all negative. Only one duodenal
MALT tested showed the IGH translocation. Unfortu-
nately, due to the absence of karyotype analysis, we
could not further determine the partner gene for this
case. Nevertheless, our data corroborates the prior data
that an IGH translocation (such as the IGH-MALT1,
IGH-BCL10, IGH-FOXP1), which is not the same as a
clonal IGH gene rearrangement detected by polymerase
chain reaction analysis, is an infrequent genetic alter-
ation in the pathogenesis of gastric MALTs.
In summary, our study highlights the differences in
distribution and subtype of GI lymphomas at a large
North American medical center. Secondary GI lymph-
omas were less frequent than primary GI lymphomas,
and there were clear differences in frequency and sub-
type between primary and secondary cases. We confirm
that certain genetic alterations occur frequently in GI
lymphomas, such as loss of P16 protein expression and
API2-MALT1 translocations in gastric MALTs, and P53
overexpression in gastric DLBCLs. However, we also
found differences in the subtype, molecular, and clinical
features in our Central-Midwestern North American pa-
tient population compared to other non-North Ameri-
can series.
Additional files
Additional file 1: Table S1. Subtype and site of involvement of
gastrointestinal lymphomas seen at a North American Medical center
from 2000-2009.
Additional file 2: Table S2. Demographics of primary gastrointestinal
lymphomas seen at a North American medical center from 2000-2009.
Additional file 3: Table S3. Immmunophenotype, P16 and P53
expression, proliferative index, clinical and molecular features in gastric
lymphomas.
Abbreviations
GI: Gastrointestinal; MALT: Extranodal marginal zone lymphoma of mucosal
associated lymphoid tissue; DLBCL: Diffuse large B cell lymphoma;
IGH: Immunoglobulin heavy chain gene; HP: Helicobacter pylori; FL: Follicular
lymphoma; ALCL: Anaplastic large cell lymphoma; MCL: Mantle cell
lymphoma; BL: Burkitt lymphoma; FISH: Fluorescence in situ hybridization;
US: United States.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JW helped design the study, performed the epidemiological and
immunohistochemical data analysis, and drafted the manuscript. JL
performed statistical data analysis. DR and JB performed the cytogenetic
data analysis. JLF helped design the project, contributed cases to the study,
and helped write the manuscript. FK and AH contributed cases to the study,
and helped write the manuscript. TN designed the study, coordinated the
research efforts, carried out the histologic, immunohistochemical, and
epidemiologic data review, and drafted the manuscript. All authors read and
approved the final manuscript.
Author details
1Department of Pathology & Immunology, Washington University Medical
School, 660 S. Euclid Ave, Campus Box 8118, St. Louis, MO 63110, USA.
2Department of Biostatistics, Washington University Medical School, St. Louis,
MO, USA.
Received: 2 March 2012 Accepted: 22 May 2012
Published: 28 June 2012
References
1. Crump M, Gospodarowicz M, Shepherd FA: Lymphoma of the
gastrointestinal tract. Semin Oncol 1999, 26:324–337.
2. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-
Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rube C, Probst
A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A,
Parwaresch R, Tiemann M: Primary gastrointestinal non-Hodgkin's
lymphoma: I. Anatomic and histologic distribution, clinical features, and
survival data of 371 patients registered in the German Multicenter Study
GIT NHL 01/92. J Clin Oncol 2001, 19:3861–3873.
3. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M: Primary
gastrointestinal lymphoma in Japan: a clinicopathologic analysis of
Warrick et al. Diagnostic Pathology 2012, 7:76 Page 7 of 9
http://www.diagnosticpathology.org/content/7/1/76
455 patients with special reference to its time trends. Cancer 2003,
97:2462–2473.
4. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G,
Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary
gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of
128 cases in Greece. A Hellenic Cooperative Oncology Group study
(HeCOG). Leuk Lymphoma 2006, 47:2140–2146.
5. Krugmann J, Dirnhofer S, Gschwendtner A, Berresheim U, Greil R, Krugmann K,
Fend F: Primary gastrointestinal B-cell lymphoma. A clincopathological and
immunohistochemical study of 61 cases with an evaluation of prognostic
parameters. Pathol Res Pract 2001, 197:385–393.
6. Fischbach W, Dragosics B, Kolve-Goebeler ME, Ohmann C, Greiner A, Yang Q,
Bohm S, Verreet P, Horstmann O, Busch M, Duhmke E, Muller-Hermelink HK,
Wilms K, Allinger S, Bauer P, Bauer S, Bender A, Brandstatter G, Chott A, Dittrich C,
Erhart K, Eysselt D, Ellersdorfer H, Ferlitsch A, Fridrik MA, Gartner A,
Hausmaninger M, Hinterberger W, Hugel K, Ilsinger P, et al: Primary gastric B-
cell lymphoma: results of a prospective multicenter study. The German-
Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000,
119:1191–1202.
7. Hansen PB, Vogt KC, Skov RL, Pedersen-Bjergaard U, Jacobsen M, Ralfkiaer E:
Primary gastrointestinal non-Hodgkin's lymphoma in adults: a
population-based clinical and histopathologic study. J Intern Med 1998,
244:71–78.
8. Halme L, Mecklin JP, Juhola M, Krees R, Palmu A: Primary gastrointestinal
non- Hodgkin's lymphoma. A population based study in central Finland
in 1975–1993. Acta Oncol 1997, 36:69–74.
9. Mihaljevic B, Nedeljkov-Jancic R, Vujicic V, Antic D, Jankovic S, Colovic N:
Primary extranodal lymphomas of gastrointestinal localizations: a single
institution 5-yr experience. Med Oncol 2006, 23:225–235.
10. Andrews CN, John Gill M, Urbanski SJ, Stewart D, Perini R, Beck P: Changing
epidemiology and risk factors for gastrointestinal non-Hodgkin's
lymphoma in a North American population: population-based study. Am
J Gastroenterol 2008, 103:1762–1769.
11. Contreary K, Nance FC, Becker WF: Primary lymphoma of the
gastrointestinal tract. Ann Surg 1980, 191:593–598.
12. Weingrad DN, Decosse JJ, Sherlock P, Straus D, Lieberman PH, Filippa DA:
Primary gastrointestinal lymphoma: a 30-year review. Cancer 1982,
49:1258–1265.
13. Forman D, Pisani P: Gastric cancer in Japan–honing treatment, seeking
causes. N Engl J Med 2008, 359:448–451.
14. Sagaert X, De Wolf-Peeters C, Noels H, Baens M: The pathogenesis of MALT
lymphomas: where do we stand? Leukemia 2007, 21:389–396.
15. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA: Cell cycle deregulation in
B-cell lymphomas. Blood 2003, 101:1220–1235.
16. Takino H, Okabe M, Li C, Ohshima K, Yoshino T, Nakamura S, Ueda R, Eimoto T,
Inagaki H: p16/INK4a gene methylation is a frequent finding in pulmonary
MALT lymphomas at diagnosis. Mod Pathol 2005, 18:1187–1192.
17. Du MQ, Isaccson PG: Gastric MALT lymphoma: from aetiology to
treatment. Lancet Oncol 2002, 3:97–104.
18. Farinha P, Gascoyne RD: Molecular pathogenesis of mucosa-associated
lymphoid tissue lymphoma. J Clin Oncol 2005, 23:6370–6378.
19. Dierlamm J, Stefanova M, Wlodarska I, Hinz K, Maes B, Michaux L, Stul M,
Verhoef G, Thomas J, De Wolf-Peeters C, Van den Berghe H, Hossfeld DK,
Hagemeijer A: Analysis of the P53, RB/D13S25, and P16 tumor suppressor
genes in marginal zone B-cell lymphoma: An interphase fluorescence in
situ hybridization study. Cancer Genet Cytogenet 2000, 120:1–5.
20. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas
C, Robledo M, Benitez J: Hypermethylation of a 5' CpG island of p16 is a
frequent event in non-Hodgkin's lymphoma. Leukemia 1997, 11:425–428.
21. Park S, Kim KM, Kim JJ, Lee JH, Rhee JC, Ko YH: Methylation of p16INK4A
and mitotic arrest defective protein 2 (MAD2) genes in gastric marginal-
zone B-cell lymphomas. Acta Haematol 2008, 120:217–224.
22. Min KO, Seo EJ, Kwon HJ, Lee EJ, Kim WI, Kang CS, Kim KM: Methylation of
p16(INK4A) and p57(KIP2) are involved in the development and
progression of gastric MALT lymphomas. Mod Pathol 2006, 19:141–148.
23. Lewin KJ, Ranchod M, Dorfman RF: Lymphomas of the gastrointestinal
tract: a study of 117 cases presenting with gastrointestinal disease.
Cancer 1978, 42:693–707.
24. Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW:
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon:
IARC; 2008.
25. Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P,
Lister TA, Norton A, Salem P, Shipp M, et al: Report on a workshop convened
to discuss the pathological and staging classifications of gastrointestinal
tract lymphoma. Ann Oncol 1994, 5:397–400.
26. Ruskone-Fourmestraux A, Delmer A, Hennequin C: Gastro-intestinal
lymphomas. Gastroenterol Clin Biol 2006, 30(2):2S81–2S90.
27. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R,
Forsyth P, Rich K, Perry A: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-
FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol
2004, 63:314–322.
28. Andriani A, Zullo A, Di Raimondo F, Patti C, Tedeschi L, Recine U, Caruso L,
Bonanno G, Chiarenza A, Lizzani G, Miedico A, Romanelli A, Costa A, Linea C,
Marrone C, Mirto S, Mistretta A, Montalbano L, Restivo G, Vinci M, Bibas M,
Hassan C, Stella F, Cottone M, Morini S: Clinical and endoscopic presentation
of primary gastric lymphoma: a multicentre study. Aliment Pharmacol Ther
2006, 23:721–726.
29. Erkurt MA, Aydogdu I, Kuku I, Kaya E, Basaran Y: Clinicopathologic
characteristics and therapeutic outcomes of primary gastrointestinal
non-Hodgkin's lymphomas: 10 years of experience from a single center
in eastern Anatolia. Med Princ Pract 2009, 18:399–406.
30. Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M, Dewald GW,
Kurtin PJ: The incidence and anatomic site specificity of chromosomal
translocations in primary extranodal marginal zone B-cell lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma) in North America.
Am J Surg Pathol 2006, 30:1546–1553.
31. Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C,
Maurschhauser F, Bouabdallah R, Leblond V, Lefrere F, Bouscary D, Audouin J,
Coiffier B, Varet B, Molina T, Brousse N, Hermine O: Primary follicular
lymphoma of the gastrointestinal tract: a study of 25 cases and a literature
review. Ann Oncol 2003, 14:623–629.
32. Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, Ferry JA: Primary follicular
lymphoma of the gastrointestinal tract. Am J Surg Pathol 2011, 35:1255–1263.
33. Zullo A, Hassan C, Cristofari F, Perri F, Morini S: Gastric low-grade mucosal-
associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond.
World J Gastrointest Oncol 2010, 2:181–186.
34. Cuttner J, Werther JL, McGlynn P, Chen A, Bodian C, Ogata S, Strauchen J,
Troy K, Itzkowitz S: Seroprevalence of Helicobacter pylori infection in
patients with lymphoma. Leuk Lymphoma 2001, 40:591–597.
35. Zullo A, Hassan C, Andriani A, Cristofari F, Cardinale V, Spinelli GP, Tomao S,
Morini S: Primary low-grade and high-grade gastric MALT-lymphoma
presentation. J Clin Gastroenterol 2010, 44:340–344.
36. Kondo T, Oka T, Sato H, Shinnou Y, Washio K, Takano M, Morito T, Takata K,
Ohara N, Ouchida M, Shimizu K, Yoshino T: Accumulation of aberrant CpG
hypermethylation by Helicobacter pylori infection promotes development
and progression of gastric MALT lymphoma. Int J Oncol 2009, 35:547–557.
37. Neumeister P, Hoefler G, Beham-Schmid C, Schmidt H, Apfelbeck U,
Schaider H, Linkesch W, Sill H: Deletion analysis of the p16 tumor
suppressor gene in gastrointestinal mucosa-associated lymphoid tissue
lymphomas. Gastroenterology 1997, 112:1871–1875.
38. Huang Q, Ai L, Zhang ZY, Fan CY, Weiss LM: Promoter hypermethylation
and protein expression of the p16 gene: analysis of 43 cases of B-cell
primary gastric lymphomas from China. Mod Pathol 2004, 17:416–422.
39. Yang Y, Wei ZJ, Zhai Y: The significance of p16 protein and Ki-67 antigen
expression in gastric mucosa-associated lymphoid tissue lymphoma.
Zhonghua Nei Ke Za Zhi 2008, 47:743–745.
40. Hall PA, Lane DP: p53 in tumour pathology: can we trust
immunohistochemistry?– Revisited! J Pathol 1994, 172:1–4.
41. Li HL, Sun BZ, Ma FC: Expression of COX-2, iNOS, p53 and Ki-67 in gastric
mucosa- associated lymphoid tissue lymphoma. World J Gastroenterol
2004, 10:1862–1866.
42. Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT: Disrupted p53
function as predictor of treatment failure and poor prognosis in B- and
T-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999, 5:1085–1091.
43. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y,
Hamoudi RA, Diss TC, Dogan A, Megraud F, Rambaud JC, Du MQ, Isaacson PG:
Resistance of t(11;18) positive gastric mucosa-associated lymphoid
tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001,
357:39–40.
44. Starostik P, Patzner J, Greiner A, Schwarz S, Kalla J, Ott G, Muller-Hermelink HK:
Gastric marginal zone B-cell lymphomas of MALT type develop along 2
distinct pathogenetic pathways. Blood 2002, 99:3–9.
Warrick et al. Diagnostic Pathology 2012, 7:76 Page 8 of 9
http://www.diagnosticpathology.org/content/7/1/76
45. Schreuder MI, Hoeve MA, Hebeda KM, Verdijk MA, Ligtenberg MJ, Bot FJ,
Chott A, van Krieken JH: Mutual exclusion of t(11;18)(q21;q21) and
numerical chromosomal aberrations in the development of different
types of primary gastric lymphomas. Br J Haematol 2003, 123:590–599.
46. Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Kerr L, Banham AH, Streubel B,
Yao T, Tsuneyoshi M, Savio A, Takeshita M, Dartigues P, Ruskone-Fourmestraux A,
Matsumoto T, Iida M, Du MQ: Translocations involving the immunoglobulin
heavy chain gene locus predict better survival in gastric diffuse large B-cell
lymphoma. Clin Cancer Res 2008, 14:3002–3010.
47. Huang X, Zhang Z, Liu H, Ye H, Chuang SS, Wang J, Lin S, Gao Z, Du MQ: t
(11;18)(q21;q21) in gastric MALT lymphoma and diffuse large B-cell
lymphoma of Chinese patients. Hematol J 2003, 4:342–345.
48. Barth TF, Bentz M, Leithauser F, Stilgenbauer S, Siebert R, Schlotter M,
Schlenk RF, Dohner H, Moller P: Molecular-cytogenetic comparison of
mucosa-associated marginal zone B-cell lymphoma and large B-cell
lymphoma arising in the gastro-intestinal tract. Genes Chromosomes
Cancer 2001, 31:316–325.
49. Wang G, Auerbach A, Wei M, Dow N, Barry TS, Hodge L, Schaffer D, Sobin LH,
Aguilera NS: t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma
of mucosa-associated lymphoid tissue in stomach: a study of 48 cases.
Mod Pathol 2009, 22:79–86.
doi:10.1186/1746-1596-7-76
Cite this article as: Warrick et al.: Gastrointestinal lymphomas in a North
American population: clinicopathologic features from one major
Central-Midwestern United States tertiary care medical center.
Diagnostic Pathology 2012 7:76.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Warrick et al. Diagnostic Pathology 2012, 7:76 Page 9 of 9
http://www.diagnosticpathology.org/content/7/1/76
